Endocrine Abstracts

Background: Hypoparathyroidism (HP) is caused by a group of heterogenous conditions that result in deficient secretion of parathyroid hormone. Due to this heterogenous nature, information on HP prevalence is highly variable and studies can be difficult to compare. This study aims to estimate the true prevalence of HP within the EU via comparison of available literature and analyses of sub-populations.Methods: MEDLINE and EMBASE were systematically search...

Background: Hypoparathyroidism (HP), a condition of parathyroid hormone (PTH) deficiency, leads to abnormal calcium metabolism. Standard of care (SOC), ie, large amounts of calcium and active vitamin D, leads to hypercalciuria and increased calcium x phosphate. Daily Natpara, PTH(1-84), injections reduced calcium and active vitamin D doses but not 24-hour urinary calcium (uCa) excretion or incidence of hypo- and hypercalcemia due to its 3-hour half-life (Natpara label). NIH st...

Background: Hypoparathyroidism (HP) is characterized by low serum calcium (sCa) and high serum phosphate (sP). Standard of care (SoC), active vitamin D and calcium, raises sCa and sP and increases burden of illness on HP patients by worsening hypercalciuria and the CaxP product. Parathyroid hormone (PTH)(1–84)(t1/2 ~2–3 hrs) is approved and can raise sCa and allow partial withdrawal of SoC, but does not sufficiently control urine calcium or symptoma...